Haverford Trust Co Purchases Shares of 5,703 Danaher Corporation $DHR

Key Points

• Haverford Trust Co. acquired 5,703 Danaher shares during the second quarter, valued at approximately $4.1 million. Institutional investors collectively own 79.05% of Danaher’s outstanding stock.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $228.91; individual targets range up to $240.
• Danaher’s latest quarterly results exceeded expectations, with EPS of $1.94 versus the $1.85 estimate and revenue of $6.26 billion, up 5.5% year over year.

Haverford Trust Co acquired a new position in Danaher Corporation (NYSE:DHR - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,703 shares of the conglomerate's stock, valued at approximately $4,106,000.

Other hedge funds have also made changes to their positions in the company. Main Street Group LTD acquired a new position in shares of Danaher during the 1st quarter valued at $25,000. N.E.W. Advisory Services LLC acquired a new stake in Danaher in the 2nd quarter valued at $25,000. JPL Wealth Management LLC purchased a new position in Danaher in the third quarter valued at about $25,000. WFA of San Diego LLC purchased a new position in Danaher in the second quarter valued at about $26,000. Finally, Hilton Head Capital Partners LLC purchased a new position in Danaher in the fourth quarter valued at about $27,000. Hedge funds and other institutional investors own 79.05% of the company's stock.

Wall Street Analysts Forecast Growth

DHR has been the subject of a number of recent research reports. Citigroup assumed coverage on Danaher in a research note on Tuesday, May 26th. They issued a "buy" rating and a $230.00 target price for the company. Wall Street Zen lowered Danaher from a "buy" rating to a "hold" rating in a research report on Saturday, April 25th. Weiss Ratings raised shares of Danaher from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday, July 15th. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and set a $240.00 price objective on shares of Danaher in a research note on Wednesday, July 22nd. Finally, HSBC reduced their target price on shares of Danaher from $270.00 to $230.00 and set a "buy" rating on the stock in a research report on Wednesday, June 3rd. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $228.91.

Danaher Stock Up 1.6%

Shares of NYSE DHR opened at $219.42 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80. The stock's 50-day simple moving average is $195.80 and its 200-day simple moving average is $192.61. The firm has a market cap of $154.25 billion, a price-to-earnings ratio of 38.97, a PEG ratio of 2.72 and a beta of 0.78.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.85 by $0.09. The business had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business's revenue was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.77 earnings per share. As a group, equities analysts anticipate that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Profile

Danaher Corporation NYSE: DHR is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher's portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source